MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy

Overview

Journal Reprod Sci

Publisher Springer

Specialty Reproductive Medicine

Date 2021 Feb 11

PMID 33569751

Citations 10

Authors

Yalda Baghay Esfandyari

Mohammad Amin Doustvandi

Mohammad Amini

Behzad Baradaran

Sheyda Jodeiry Zaer

Nazila Mozammel

Mehdi Mohammadzadeh

Ahad Mokhtarzadeh

Affiliations

Soon will be listed here.

Abstract

Cisplatin-based chemotherapy is commonly used for cervical cancer treatment. However, the development of chemoresistance is considered the main obstacle to the effectiveness of this therapeutic agent. MicroRNAs are illustrated to play a major role in the regulation of cancer cell chemosensitivity. Therefore, this study was aimed to investigate the potential therapeutic role of miRNA-143 in combination with cisplatin on cervical cancer cells. Then, CaSki cell line with low expression levels of miRNA-143 was selected for functional experiments. The cells were treated with miRNA-143 and cisplatin individually or in combination. The cell viability and apoptosis induction were evaluated by MTT, Annexin V-FITC/PI, and DAPI staining tests. Cell migration was further evaluated by wound healing assay. The effect of miRNA-143 and cisplatin combination on gene expression was quantified by real-time PCR. Furthermore, the combination therapy effect on cell cycle progression and autophagy induction was also evaluated by flow cytometry. Our results showed that miRNA-143 overexpression could increase cisplatin-induced apoptosis and increase the sensitivity of CaSki cells to low doses of this chemotherapeutic agent via modulating the expression of apoptosis-related genes including Bcl-2, Bax, and caspase-9. Besides, miRNA-143 and cisplatin were demonstrated to cooperatively increase the cell cycle arrest at the sub-G1 and G2-M phases, induce autophagy activation, and via downregulation of vimentin inhibit CaSki cell migration. Moreover, c-Myc as an important regulator of cell growth was downregulated in treatment groups compared to the control. In conclusion, regarding that miRNA-143 could sensitize cervical cancer cells to cisplatin, it may be considered a promising therapeutic strategy for the treatment of this malignancy.

Citing Articles

Simultaneous effect of miR-21 suppression and miR-143 restoration on inhibition of proliferation and migration in SW-480 colorectal cancer cells.

Tohidast M, Amini M, Doustvandi M, Hosseini S, Bilan F, Mozammel N Bioimpacts. 2025; 15:30255.

PMID: 39963562 PMC: 11830141. DOI: 10.34172/bi.30255.

The Roles of Autophagy-related miRNAs in Gynecologic Tumors: A Review of Current Knowledge for Possible Targeted Therapy.

Mobinikhaledi M, Faridzadeh A, Farkhondeh T, Pourhanifeh M, Samarghandian S Curr Mol Med. 2024; 24(10):1269-1281.

PMID: 39300715 DOI: 10.2174/0115665240263059231002093454.

Cooperatively inhibition effect of miR-143-5p and miR-145-5p in tumorigenesis of glioblastoma cells through modulating AKT signaling pathway.

Zaer S, Aghamaali M, Amini M, Doustvandi M, Hosseini S, Baradaran B Bioimpacts. 2024; 14(3):29913.

PMID: 38938754 PMC: 11199930. DOI: 10.34172/bi.2023.29913.

Simultaneous suppression of miR-21 and restoration of miR-145 in gastric cancer cells; a promising strategy for inhibition of cell proliferation and migration.

Bilan F, Amini M, Doustvandi M, Tohidast M, Baghbanzadeh A, Hosseini S Bioimpacts. 2024; 14(2):27764.

PMID: 38505672 PMC: 10945301. DOI: 10.34172/bi.2023.27764.

HPV16 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway.

Konstantopoulos G, Leventakou D, Saltiel D, Zervoudi E, Logotheti E, Pettas S Viruses. 2024; 16(1).

PMID: 38257813 PMC: 10819893. DOI: 10.3390/v16010113.

References

Nahand J, Taghizadeh-Boroujeni S, Karimzadeh M, Borran S, Pourhanifeh M, Moghoofei M . microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. J Cell Physiol. 2019; 234(10):17064-17099. DOI: 10.1002/jcp.28457. View

Leekha A, Gurjar B, Tyagi A, Rizvi M, Verma A . Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. J Cancer Res Clin Oncol. 2016; 142(12):2503-2514. DOI: 10.1007/s00432-016-2235-z. View

Wang L, Dai G, Yang J, Wu W, Zhang W . Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097. Med Sci Monit. 2018; 24:4046-4053. PMC: 6032799. DOI: 10.12659/MSM.909452. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Asadzadeh Z, Mansoori B, Mohammadi A, Aghajani M, Haji-Asgarzadeh K, Safarzadeh E . microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities. J Cell Physiol. 2018; 234(7):10002-10017. DOI: 10.1002/jcp.27885. View

Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B . Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci. 2018; 213:236-247. DOI: 10.1016/j.lfs.2018.10.009. View

Yu M, Xu B, Yang H, Xue S, Zhang R, Zhang H . MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin. Cancer Manag Res. 2019; 11:6511-6519. PMC: 6636183. DOI: 10.2147/CMAR.S199659. View

Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R . An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci. 2019; 240:117077. DOI: 10.1016/j.lfs.2019.117077. View

Osada H, Takahashi T . MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2006; 28(1):2-12. DOI: 10.1093/carcin/bgl185. View

10.

Iorio M, Croce C . microRNA involvement in human cancer. Carcinogenesis. 2012; 33(6):1126-33. PMC: 3514864. DOI: 10.1093/carcin/bgs140. View

11.

Rezaei T, Hejazi M, Mansoori B, Mohammadi A, Amini M, Mosafer J . microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis. Eur J Pharmacol. 2020; 888:173483. DOI: 10.1016/j.ejphar.2020.173483. View

12.

Zhou M, Chen X, Wu J, He X, Ren R . MicroRNA-143 regulates cell migration and invasion by targeting GOLM1 in cervical cancer. Oncol Lett. 2018; 16(5):6393-6400. PMC: 6202488. DOI: 10.3892/ol.2018.9441. View

13.

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

14.

Viegas S, Arraiano C . Regulating the regulators: How ribonucleases dictate the rules in the control of small non-coding RNAs. RNA Biol. 2008; 5(4):230-43. DOI: 10.4161/rna.6915. View

15.

Prabhakar B, Zhong X, Rasmussen T . Exploiting Long Noncoding RNAs as Pharmacological Targets to Modulate Epigenetic Diseases. Yale J Biol Med. 2017; 90(1):73-86. PMC: 5369047. View

16.

Ghasabi M, Mansoori B, Mohammadi A, Duijf P, Shomali N, Shirafkan N . MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. J Cell Physiol. 2018; 234(3):2152-2168. DOI: 10.1002/jcp.26810. View

17.

Gambari R, Brognara E, Spandidos D, Fabbri E . Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 2016; 49(1):5-32. PMC: 4902075. DOI: 10.3892/ijo.2016.3503. View

18.

Hosseinahli N, Aghapour M, Duijf P, Baradaran B . Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 2018; 233(8):5574-5588. DOI: 10.1002/jcp.26514. View

19.

Tavanafar F, Safaralizadeh R, Hosseinpour-Feizi M, Mansoori B, Shanehbandi D, Mohammadi A . Restoration of miR-143 expression could inhibit migration and growth of MDA-MB-468 cells through down-regulating the expression of invasion-related factors. Biomed Pharmacother. 2017; 91:920-924. DOI: 10.1016/j.biopha.2017.04.119. View

20.

Li J, Liu Q, Clark L, Qiu H, Bae-Jump V, Zhou C . Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use. Future Oncol. 2016; 13(8):743-753. DOI: 10.2217/fon-2016-0328. View